Noralane M Lindor

List of Publications by Year in Descending Order

74 papers	3,129 citations	27 h-index	55 g-index
74 ext. papers	3,839 ext. citations	7.5 avg, IF	4.48 L-index

#	Paper	IF	Citations
74	Penetrance and outcomes at 1-year following return of actionable variants identified by genome sequencing. *Genetics in Medicine*, **2021**, 23, 1192-1201	8.1	1
73	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. *Gastroenterology*, **2021**, 160, 1164-1178.e6	13.3	15
72	Increasing access to individualized medicine: a matched-cohort study examining Latino participant experiences of genomic screening. *Genetics in Medicine*, **2021**, 23, 934-941	8.1	2
71	Experiences of Latino Participants Receiving Neutral Genomic Screening Results: A Qualitative Study. *Public Health Genomics*, **2021**, 24, 44-53	1.9	1
70	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
69	Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1800-1808	4	1
68	Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study. *Npj Genomic Medicine*, **2020**, 5, 19	6.2	2
67	Contribution of mRNA Splicing to Mismatch Repair Gene Sequence Variant Interpretation. *Frontiers in Genetics*, **2020**, 11, 798	4.5	5
66	Potential impact of family history-based screening guidelines on the detection of early-onset colorectal cancer. *Cancer*, **2020**, 126, 3013-3020	6.4	23
65	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. *Hereditary Cancer in Clinical Practice*, **2019**, 17, 28	2.3	16
64	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. *Nature Communications*, **2019**, 10, 2154	17.4	81
63	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. *Hereditary Cancer in Clinical Practice*, **2019**, 17, 8	2.3	24
62	Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. *Genetics in Medicine*, **2019**, 21, 71-80	8.1	36
61	Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients. *Journal of Immigrant and Minority Health*, **2019**, 21, 434-437	2.2	8
60	Risks of Colorectal Cancer and Cancer-Related Mortality in Familial Colorectal Cancer Type X and Lynch Syndrome Families. *Journal of the National Cancer Institute*, **2019**, 111, 675-683	9.7	5
59	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
58	Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. *American Journal of Human Genetics*, **2018**, 102, 233-248	11	38

57	Physical activity and the risk of colorectal cancer in Lynch syndrome. *International Journal of Cancer*, **2018**, 143, 2250-2260	7.5	9
56	DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome. *Modern Pathology*, **2018**, 31, 1608-1618	9.8	14
55	From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. *Journal of Community Genetics*, **2018**, 9, 209-215	2.5	5
54	The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results. *Mayo Clinic Proceedings*, **2018**, 93, 1600-1610	6.4	20
53	Developing a Process for Returning Medically Actionable Genomic Variants to Latino Patients in a Federally Qualified Health Center. *Public Health Genomics*, **2018**, 21, 77-84	1.9	14
52	Leptin gene variants and colorectal cancer risk: Sex-specific associations. *PLoS ONE*, **2018**, 13, e0206519	3.7	9
51	Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. *PLoS ONE*, **2018**, 13, e0196245	3.7	2
50	Whole-Genome Sequencing in Healthy People. *Mayo Clinic Proceedings*, **2017**, 92, 159-172	6.4	33
49	Non-BRCA familial breast cancer: review of reported pathology and molecular findings. *Pathology*, **2017**, 49, 363-370	1.6	17
48	Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. *International Journal of Cancer*, **2017**, 140, 2701-2708	7.5	50
47	Prediagnostic alcohol consumption and colorectal cancer survival: The Colon Cancer Family Registry. *Cancer*, **2017**, 123, 1035-1043	6.4	17
46	Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. *Oncotarget*, **2017**, 8, 93450-93463	3.3	18
45	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. *Journal of Oncology Practice*, **2017**, 13, 333-337	3.1	20
44	Long-term weight loss after colorectal cancer diagnosis is associated with lower survival: The Colon Cancer Family Registry. *Cancer*, **2017**, 123, 4701-4708	6.4	15
43	Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. *European Journal of Cancer*, **2017**, 84, 228-238	7.5	56
42	Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry. *Molecular Genetics & Genomic Medicine*, **2017**, 5, 700-708	2.3	1
41	Germline miRNA DNA variants and the risk of colorectal cancer by subtype. *Genes Chromosomes and Cancer*, **2017**, 56, 177-184	5	6
40	PMS2 monoallelic mutation carriers: the known unknown. *Genetics in Medicine*, **2016**, 18, 13-9	8.1	42

39	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
38	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
37	Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). *Carcinogenesis*, **2016**, 37, 751-8	4.6	9
36	CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. *British Journal of Cancer*, **2016**, 114, 221-9	8.7	16
35	Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease. *Human Molecular Genetics*, **2016**, 25, 2349-2359	5.6	27
34	The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. *New England Journal of Medicine*, **2016**, 374, 454-68	59.2	179
33	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
32	Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic Experience. *Mayo Clinic Proceedings*, **2016**, 91, 297-307	6.4	63
31	Genome-Wide Interaction Analyses between Genetic Variants and Alcohol Consumption and Smoking for Risk of Colorectal Cancer. *PLoS Genetics*, **2016**, 12, e1006296	6	30
30	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
29	Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. *British Journal of Cancer*, **2016**, 115, 266-72	8.7	39
28	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. *American Journal of Human Genetics*, **2016**, 98, 830-842	11	153
27	Estimating cumulative risks for breast cancer for carriers of variants in uncommon genes. *Familial Cancer*, **2016**, 15, 367-70	3	3
26	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
25	A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. *Scientific Reports*, **2015**, 5, 10442	4.9	94
24	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
23	Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1133-42	27.4	135
22	A genome-wide association study for colorectal cancer identifies a risk locus in 14q23.1. *Human Genetics*, **2015**, 134, 1249-1262	6.3	25

21	Response to ten Broeke and Nielsen. *Genetics in Medicine*, **2015**, 17, 684-5	8.1	
20	Myhre-LAPs syndrome and intubation related airway stenosis: keys to diagnosis and critical therapeutic interventions. *American Journal of Otolaryngology - Head and Neck Medicine and Surgery* , **2015**, 36, 636-41	2.8	9
19	Whole-Exome Sequencing of 10 Scientists: Evaluation of the Process and Outcomes. *Mayo Clinic Proceedings*, **2015**, 90, 1327-37	6.4	9
18	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
17	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. *Scientific Reports*, **2015**, 5, 17369	4.9	27
16	Preferences Regarding Return of Genomic Results to Relatives of Research Participants, Including after Participant Death: Empirical Results from a Cancer Biobank. *Journal of Law, Medicine and Ethics*, **2015**, 43, 464-75	1.2	21
15	Returning a Research Participant'S Genomic Results to Relatives: Analysis and Recommendations. *Journal of Law, Medicine and Ethics*, **2015**, 43, 440-63	1.2	67
14	How well do whole exome sequencing results correlate with medical findings? A study of 89 Mayo Clinic Biobank samples. *Frontiers in Genetics*, **2015**, 6, 244	4.5	8
13	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
12	Mendelian Randomization Study of Body Mass Index and Colorectal Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1024-31	4	54
11	Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1229-38	4	38
10	A preliminary investigation of genetic counselorsSinformation needs when receiving a variant of uncertain significance result: a mixed methods study. *Genetics in Medicine*, **2015**, 17, 739-46	8.1	20
9	Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. *Human Molecular Genetics*, **2014**, 23, 4729-37	5.6	107
8	Colorectal cancer and self-reported tooth agenesis. *Hereditary Cancer in Clinical Practice*, **2014**, 12, 7	2.3	13
7	Genomic medicine and incidental findings: balancing actionability and patient autonomy. *Mayo Clinic Proceedings*, **2014**, 89, 718-21	6.4	11
6	Lynch syndrome 101 (years, that is). *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2014**, 27-32	7.1	2
5	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
4	Family history of colorectal cancer is not associated with colorectal cancer survival regardless of microsatellite instability status. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1700-4	4	8

3	BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. *Oncologist*, **2013**, 18, 518-24	5.7	61
2	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
1	Central pontine myelinolysis as a complication of partial ornithine carbamoyl transferase deficiency. *American Journal of Medical Genetics Part A*, **1995**, 60, 210-3		16